MDCXW
Medicus Pharma Ltd.
Price Chart
Latest Quote
$0.35
-0.11 (-23.91%)
Current Price
| Previous Close | $0.46 |
| Open | $0.99 |
| Day High | $0.35 |
| Day Low | $0.34 |
| Volume | 9,473 |
Stock Information
| Total Debt | $2.53M |
| Cash Equivalents | $6.37M |
| Net Income | $-51.22M |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Income | $-51.22M |
| Book/sh | $0.03 |
| Employees | 16 |
Financial Ratios
| Quick Ratio | 1.07 |
| Current Ratio | 1.22 |
| Debt/Eq | 177.50 |
Returns & Margins
| ROA | -278.11% |
| ROE | -2865.18% |
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | 10.61 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.66 |
| SMA50 | $0.67 |
| SMA200 | $1.83 |
| ATR | 0.0243 |
| Shares Float | 50.17M |
| Volatility | -0.50 |
| Rel Volume | 20.00 |
Performance History
| Week | -48.49% |
| Month | -48.49% |
| Quarter | -48.49% |
| 6 Months | -86.00% |
| YTD | -86.00% |
| Year | -86.00% |
| 10 Years | -86.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $0.35 | 9,473 |
| 2026-06-18 | $0.68 | 0 |
| 2026-06-17 | $0.68 | 0 |
| 2026-06-16 | $0.68 | 0 |
| 2026-06-15 | $0.68 | 0 |
| 2026-06-12 | $0.68 | 0 |
| 2026-06-11 | $0.68 | 0 |
| 2026-06-10 | $0.68 | 0 |
| 2026-06-09 | $0.68 | 0 |
| 2026-06-08 | $0.68 | 0 |
| 2026-06-05 | $0.68 | 0 |
| 2026-06-04 | $0.68 | 0 |
| 2026-06-03 | $0.68 | 0 |
| 2026-06-02 | $0.68 | 0 |
| 2026-06-01 | $0.68 | 0 |
| 2026-05-29 | $0.68 | 0 |
| 2026-05-28 | $0.68 | 0 |
| 2026-05-27 | $0.68 | 0 |
| 2026-05-26 | $0.68 | 0 |
About Medicus Pharma Ltd.
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was incorporated in 2008 and is headquartered in West Conshohocken, Pennsylvania.
đ° Latest News
Medicus Pharma advances Teverelix in prostate cancer - ICYMI
Proactive âĸ 2026-06-20T13:00:00Z
Medicus Pharma seeks rare pediatric disease tag for SkinJect in Gorlin Syndrome
Proactive âĸ 2026-06-15T12:47:00Z
Medicus Pharma submits EU clinical trial modification for prostate cancer drug Teverelix
Proactive âĸ 2026-06-08T12:50:00Z
Medicus Pharma advances SkinJect for Gorlin syndrome â ICYMI
Proactive âĸ 2026-06-06T15:26:00Z
Medicus Pharma advances SkinJect toward registrational trial for rare Gorlin Syndrome
Proactive âĸ 2026-06-05T15:43:57Z
Medicus Pharma advances SkinJect program with FDA submission targeting Gorlin Syndrome
Proactive âĸ 2026-06-03T13:09:00Z
Medicus Pharma Ltd. (MDCXW) Reports FDA Progress and Expands 2026 Clinical Outlook
Insider Monkey âĸ 2026-05-19T11:10:49Z
Medicus Pharma sees catalyst-rich year ahead as SkinJect and Teverelix progress
Proactive âĸ 2026-05-15T12:28:00Z
EXCLUSIVE: Medicus Sees Strongest Efficacy At Higher Dose In Skin Cancer Study
Benzinga âĸ 2026-05-07T23:31:06Z
Medicus Pharma reports strong Phase 2 dose response in skin cancer study
Proactive âĸ 2026-05-06T16:12:15Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $34,359,302 | $11,180,902 | $2,658,365 | $978,416 |
| Other Income Expense | $-887,677 | $238,517 | $-2,071,580 | $388,306 |
| Net Non Operating Interest Income Expense | $-197,382 | $25,386 | $-584,820 | $-1,102,272 |
| Total Other Finance Cost | $197,382 | $-25,386 | $584,820 | $575,447 |
| Operating Expense | $34,359,302 | $11,180,902 | $2,658,365 | $978,416 |
| General And Administrative Expense | $17,920,391 | $7,653,116 | $2,464,787 | $332,032 |
| Interest Expense | - | $902,362 | $739,096 | $526,825 |
| Interest Expense Non Operating | - | $902,362 | $739,096 | $526,825 |
| Other Non Operating Income Expenses | - | - | $-3,271,462 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-35,444,215 | $-11,155,516 | $-5,314,765 | $-1,692,382 |
| Net Interest Income | $-197,382 | $25,386 | $-584,820 | $-1,102,272 |
| Normalized Income | $-34,556,538 | $-11,155,516 | $-3,243,185 | $-2,080,688 |
| Net Income From Continuing And Discontinued Operation | $-35,444,215 | $-11,155,516 | $-5,314,765 | $-1,692,382 |
| Total Operating Income As Reported | $-34,359,302 | $-11,180,902 | $-4,729,945 | $-978,416 |
| Net Income Common Stockholders | $-47,281,513 | $-11,155,516 | $-5,314,765 | $-1,692,382 |
| Net Income | $-35,444,215 | $-11,155,516 | $-5,314,765 | $-1,692,382 |
| Net Income Including Noncontrolling Interests | $-35,444,361 | $-11,155,516 | $-5,314,765 | $-1,692,382 |
| Net Income Continuous Operations | $-35,444,361 | $-11,155,516 | $-5,314,765 | $-1,692,382 |
| Pretax Income | $-35,444,361 | $-11,155,516 | $-5,314,765 | $-1,692,382 |
| Special Income Charges | $-303,854 | $0 | $-2,071,580 | $592,901 |
| Operating Income | $-34,359,302 | $-11,180,902 | $-2,658,365 | $-978,416 |
| Interest Income | - | $104,411 | - | - |
| Interest Income Non Operating | - | $104,411 | - | - |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-33,471,625 | $-11,180,902 | $-586,785 | $-1,553,863 |
| Total Unusual Items | $-887,677 | $0 | $-2,071,580 | $388,306 |
| Total Unusual Items Excluding Goodwill | $-887,677 | $0 | $-2,071,580 | $388,306 |
| EBITDA (Bullshit earnings) | $-34,359,302 | $-11,180,902 | $-2,658,365 | $-1,165,557 |
| EBIT | $-34,359,302 | $-11,180,902 | $-2,658,365 | $-1,165,557 |
| Diluted NI Availto Com Stockholders | $-47,281,513 | $-11,155,516 | $-5,314,765 | $-1,692,382 |
| Preferred Stock Dividends | $11,837,298 | - | - | - |
| Minority Interests | $146 | $0 | - | - |
| Other Special Charges | $303,854 | - | $2,071,580 | $-592,901 |
| Gain On Sale Of Security | $-583,823 | $238,517 | $670,103 | $-204,595 |
| Research And Development | $16,438,911 | $3,527,786 | $193,578 | $646,384 |
| Selling General And Administration | $17,920,391 | $7,653,116 | $2,464,787 | $332,032 |
| Other Gand A | $17,920,391 | $7,653,116 | $2,222,918 | $332,032 |
| Salaries And Wages | - | $1,850,103 | $241,869 | $0 |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-67,554 | $3,134,704 | $1,111,448 | $-12,198,032 |
| Total Assets | $10,061,377 | $5,646,878 | $1,893,057 | $282,652 |
| Total Non Current Assets | $170,733 | $268,571 | $0 | $0 |
| Current Assets | $9,890,644 | $5,378,307 | $1,893,057 | $282,652 |
| Current Deferred Assets | $99,305 | $0 | - | - |
| Prepaid Assets | $1,086,121 | $1,213,984 | $173,719 | $15,000 |
| Cash Cash Equivalents And Short Term Investments | $8,705,218 | $4,164,323 | $1,719,338 | $267,652 |
| Cash And Cash Equivalents | $8,705,218 | $4,164,323 | $1,719,338 | $267,652 |
| Cash Financial | - | - | $1,719,338 | $267,652 |
| Debt | ||||
| Total Debt | $5,477,003 | $322,268 | $0 | $1,531,499 |
| Long Term Debt And Capital Lease Obligation | $86,004 | $205,945 | $0 | - |
| Long Term Debt | $25,865 | - | - | - |
| Current Debt And Capital Lease Obligation | $5,390,999 | $116,323 | - | $1,531,499 |
| Current Debt | $5,245,543 | - | - | $1,531,499 |
| Net Debt | - | - | - | $1,263,847 |
| Other Current Borrowings | - | - | - | $1,381,499 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $10,024,066 | $2,512,174 | $781,609 | $12,480,684 |
| Total Non Current Liabilities Net Minority Interest | $86,004 | $205,945 | $0 | $0 |
| Current Liabilities | $9,938,062 | $2,306,229 | $781,609 | $12,480,684 |
| Current Notes Payable | $5,245,543 | $0 | $0 | $150,000 |
| Payables And Accrued Expenses | $4,246,882 | $2,048,917 | $753,843 | $99,794 |
| Payables | $3,551,773 | $1,427,071 | $376,792 | - |
| Accounts Payable | $3,435,297 | $1,284,612 | $210,842 | - |
| Other Current Liabilities | - | - | - | $10,849,391 |
| Equity | ||||
| Common Stock Equity | $-67,554 | $3,134,704 | $1,111,448 | $-12,198,032 |
| Total Equity Gross Minority Interest | $37,311 | $3,134,704 | $1,111,448 | $-12,198,032 |
| Stockholders Equity | $-67,554 | $3,134,704 | $1,111,448 | $-12,198,032 |
| Gains Losses Not Affecting Retained Earnings | $10,880 | $0 | - | - |
| Other Equity Adjustments | $10,880 | - | - | - |
| Retained Earnings | $-64,348,118 | $-28,903,903 | $-17,748,387 | $-12,392,570 |
| Other | ||||
| Ordinary Shares Number | $25,176,303 | $11,816,721 | $8,076,732 | $8,048,842 |
| Share Issued | $25,176,303 | $11,816,721 | $8,076,732 | $8,048,842 |
| Tangible Book Value | $-67,554 | $3,134,704 | $1,111,448 | $-12,198,032 |
| Invested Capital | $5,203,854 | $3,134,704 | $1,111,448 | $-10,666,533 |
| Working Capital | $-47,418 | $3,072,078 | $1,111,448 | $-12,198,032 |
| Capital Lease Obligations | $205,595 | $322,268 | $0 | - |
| Total Capitalization | $-41,689 | $3,134,704 | $1,111,448 | $-12,198,032 |
| Minority Interest | $104,865 | $0 | - | - |
| Additional Paid In Capital | $6,879,575 | $1,520,412 | $98,585 | $0 |
| Capital Stock | $57,390,109 | $30,518,195 | $18,761,250 | $194,538 |
| Common Stock | $57,390,109 | $30,518,195 | $18,761,250 | $194,538 |
| Long Term Capital Lease Obligation | $60,139 | $205,945 | $0 | - |
| Current Capital Lease Obligation | $145,456 | $116,323 | $0 | - |
| Pensionand Other Post Retirement Benefit Plans Current | $300,181 | $140,989 | $27,766 | - |
| Current Accrued Expenses | $695,109 | $621,846 | $377,051 | - |
| Dueto Related Parties Current | $116,476 | $142,459 | $165,950 | - |
| Net PPE | $170,733 | $268,571 | $0 | - |
| Gross PPE | $170,733 | $268,571 | $0 | - |
| Other Properties | $170,733 | $268,571 | - | - |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-22,776,769 | $-10,247,231 | $-4,158,264 | $-1,057,103 |
| Operating Activities | ||||
| Operating Cash Flow | $-22,776,769 | $-10,247,231 | $-4,158,264 | $-1,057,103 |
| Cash Flow From Continuing Operating Activities | $-22,776,769 | $-10,247,231 | $-4,158,264 | $-1,057,103 |
| Operating Gains Losses | $66,947 | - | - | - |
| Investing Activities | ||||
| Investing Cash Flow | $-4,619,152 | $0 | - | - |
| Cash Flow From Continuing Investing Activities | $-4,619,152 | $0 | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $18,217,431 | $7,519,716 | $0 | - |
| Financing Cash Flow | $31,939,785 | $12,692,216 | $5,609,950 | $1,246,241 |
| Cash Flow From Continuing Financing Activities | $31,939,785 | $12,692,216 | $5,609,950 | $1,246,241 |
| Net Other Financing Charges | $-790,230 | - | $5,109,950 | - |
| Net Common Stock Issuance | $18,217,431 | $7,519,716 | $0 | - |
| Common Stock Issuance | $18,217,431 | $7,519,716 | $0 | - |
| Other | ||||
| Repayment Of Debt | $-7,391,107 | $0 | - | - |
| Issuance Of Debt | $11,866,293 | $5,172,500 | $500,000 | $1,246,241 |
| Interest Paid Supplemental Data | $221,663 | $40,563 | $0 | - |
| End Cash Position | $8,705,218 | $4,164,323 | $1,719,338 | $267,652 |
| Beginning Cash Position | $4,164,323 | $1,719,338 | $267,652 | $78,514 |
| Effect Of Exchange Rate Changes | $-2,969 | $0 | - | - |
| Changes In Cash | $4,543,864 | $2,444,985 | $1,451,686 | $189,138 |
| Proceeds From Stock Option Exercised | $10,037,398 | $0 | - | - |
| Net Issuance Payments Of Debt | $4,475,186 | $5,172,500 | $500,000 | $1,246,241 |
| Net Long Term Debt Issuance | $4,475,186 | $5,172,500 | $500,000 | $1,096,241 |
| Long Term Debt Payments | $-7,391,107 | $0 | - | - |
| Long Term Debt Issuance | $11,866,293 | $5,172,500 | $500,000 | $1,096,241 |
| Net Business Purchase And Sale | $-4,619,152 | $0 | - | - |
| Purchase Of Business | $-4,619,152 | $0 | - | - |
| Change In Working Capital | $569,675 | $32,927 | $473,096 | $-78,687 |
| Change In Other Working Capital | $-99,305 | - | - | - |
| Change In Other Current Liabilities | $-142,612 | $-70,080 | $0 | - |
| Change In Payables And Accrued Expense | $458,767 | $1,143,272 | $631,815 | $-63,687 |
| Change In Accrued Expense | $-438,802 | $358,018 | $386,777 | - |
| Change In Payable | $897,569 | $785,254 | $245,038 | - |
| Change In Account Payable | $923,552 | $808,745 | $79,088 | - |
| Change In Prepaid Assets | $352,825 | $-1,040,265 | $-158,719 | $-15,000 |
| Other Non Cash Items | $10,518,776 | $162,239 | $584,820 | $713,966 |
| Stock Based Compensation | $1,512,194 | $713,119 | $98,585 | $0 |
| Net Foreign Currency Exchange Gain Loss | $41,947 | $0 | - | - |
| Net Income From Continuing Operations | $-35,444,361 | $-11,155,516 | $-5,314,765 | $-1,692,382 |
| Net Short Term Debt Issuance | - | - | $0 | $150,000 |
| Short Term Debt Issuance | - | - | $0 | $150,000 |
Fetched: 2026-06-20